2026 Shanghai CPHI | Allbiosyn Bio cordially invites you to join us!


The 2026 CPHI China, the World Pharmaceutical Ingredients Exhibition, is set to open with great fanfare in Shanghai. As a rapidly growing, innovative biotechnology company, Allbiosyn Biotechnology Co., Ltd. warmly invites both new and longstanding partners to visit our booth and join us in celebrating this premier industry event!

Allbiosyn Bio focuses on the research, development, production, and sales of core raw materials for small nucleic acid therapeutics and vaccines. Leveraging an innovative end-to-end technology platform that spans the entire value chain from nucleic acid drug R&D to manufacturing, Allbiosyn has successfully developed a portfolio of modified nucleosides and functional nucleic acid molecules, all protected by proprietary intellectual property rights.

By seamlessly integrating cutting-edge synthesis technologies, enzymatic processes, stringent quality control, and scalable manufacturing capabilities, Allbiosyn is committed to providing high‑quality core raw materials and comprehensive technical solutions for oligonucleotide synthesis.

Core Product Portfolio

Nucleosides

Modified Nucleosides

Protected Nucleosides

Succinate Nucleosides

Phosphoramidites

GalNAc Derivatives

Allbiosyn Bio consistently places technological innovation at the forefront and remains customer‑centric. We look forward to engaging in in‑depth, face‑to‑face discussions with you, exploring the boundless potential of nucleic acid therapeutics, and working together to build a brighter future!

Recent News


Allbiosyn Debuts at CPHI Shanghai 2025

Allbiosyn made its exhibition debut at CPHI Shanghai 2025, presenting novel nucleic acid raw materials including high-purity modified nucleosides, phosphoramidites, and customized nucleotide modifiers.


Allbiosyn Showcases Innovative Nucleic Acid Solutions at CPHI Shenzhen 2025

Allbiosyn recently exhibited at CPHI Shenzhen, strengthening its presence as a leading provider of nucleic acid raw materials and synthesis technologies. The event provided an ideal platform to connect with key players in the pharmaceutical and biotech industries.


2025 BIOCHINA successfully concluded! Allbiosyn Bio and 30,000 industry pioneers jointly charted a new future for nucleic acid drugs.

On March 15, 2025, the three-day 2025 E-Trade Bio-industry Conference (BIOCHINA) successfully concluded at Suzhou International Expo Center. This conference, themed "Innovation Without Borders, Collaborative Coexistence," gathered 850 top global speakers and 30,000 professional attendees, covering 50,000㎡ of exhibition space, comprehensively showcasing cutting-edge technologies and industrial potential in the biomedical field. As a leader in the nucleic acid raw material sector, Allbiosyn Bio showcased its core product matrix at the exhibition, to jointly explore the future of nucleic acid drug industrialization with global partners.

Wish to receive more updates from Allbiosyn

Stay up-to-date with the latest product releases, technology trends, and upcoming events.

Product Management
  • All
  • Product Management
  • News Information
  • Introduction Content
  • Enterprise Outlets
  • FAQ
  • Corporate Video
  • Corporate Album

Phone: +8618666985712
Email: info@allbiosyn.com

WeChat ID: 18666985712
Add: Room 502, 5th Floor, Building 11, No. 288 Huifeng North Road, Fengxian District, Shanghai, China

图片名称

Copyright © 2025 Allbiosyn Biotechnology Co., Ltd. All Rights Reserved.

Business License
%E7%AC%AC%E4%B8%80%EF%BC%8C%E6%9C%80%EF%BC%8C%E4%BC%98%E7%A7%80%EF%BC%8C%E5%A2%9E%E5%BC%BA%EF%BC%8C%E4%B8%80%E6%B5%81%EF%BC%8C%E5%8D%93%E8%B6%8A%EF%BC%8C%E9%A2%86%E5%85%88%EF%BC%8C%E5%85%88%E8%BF%9B%EF%BC%8C%E5%BC%95%E9%A2%86

Sorry,当前栏目暂无内容!

您可以查看其他栏目或返回 首页

Sorry,The current column has no content!

You can view other columns or return Home